A Look At Albertsons (ACI) Valuation As Q4 Expectations Lift Earnings And Sales Outlook

Albertsons Companies (ACI) shares are reacting to expectations that upcoming fiscal Q4 results could show adjusted EBITDA and identical sales ahead of market forecasts, with management anticipated to reiterate growth guidance for fiscal 2026.

See our latest analysis for Albertsons Companies.

The latest move backs up a 12.18% 90 day share price return and a 4.28% year to date share price gain, although the 1 year total shareholder return decline of 11.12% shows longer term momentum has been weaker.

If Albertsons' update has you rethinking where growth could come from next, this is a good moment to browse opportunities in AI infrastructure and data center suppliers through the 36 AI infrastructure stocks

With Albertsons trading below its analyst price target and carrying a mixed track record on shareholder returns, the key question is whether current estimates understate its earnings power or whether the market already reflects any potential future growth.

Most Popular Narrative: 18.2% Undervalued

At a last close of $18.05 versus a narrative fair value of $22.06, Albertsons is framed as undervalued, with the story hinging on digital, pharmacy and efficiency gains.

Modernization through technology investments, such as automation, AI driven inventory/pricing, and centralized buying, are streamlining operations, reducing labor and supply chain costs, and positioning the company for long term margin expansion and improved net earnings.

Read the complete narrative.

Curious what kind of revenue path, margin lift, and future earnings multiple have to line up to back that $22.06 number? The full narrative lays out a tight set of growth, profitability, and valuation assumptions that paint a very different picture to the recent share price moves.

Result: Fair Value of $22.06 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this depends on e-commerce catching up, and on labor and pharmacy cost pressures not proving more severe than analysts currently incorporate into their earnings paths.

Find out about the key risks to this Albertsons Companies narrative.

Next Steps

If this mix of risks and potential rewards feels finely balanced, do not wait around. Review the full picture and weigh up the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

Do not stop at one stock. Broaden your watchlist with focused ideas from the Simply Wall St Screener so you are ready when the next opportunity appears.

• Boost your watchlist with companies that look cheap on quality metrics before the crowd pays attention through the 62 high quality undervalued stocks.
• Strengthen your income stream by checking out businesses that offer robust yields and appear built to sustain them in the 13 dividend fortresses.
• Sleep easier by focusing on companies that pair financial resilience with lower risk scores using the 68 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com